On January 5, 2023 Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, reported the second and third programs under the company’s global partnership with AbbVie have advanced into lead generation (Press release, Frontier Medicines, JAN 5, 2023, View Source [SID1234630855]). These programs harness novel E3 Ligases for targeted protein degradation, through the discovery of small molecules from The FrontierTM Platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our collaboration with Frontier is continuing to make progress against difficult-to-drug protein targets" said Jonathon Sedgwick, Ph.D., vice president and global head, Discovery Research, AbbVie. "Two years into our partnership, Frontier’s technology is showing important advances in the drugging of previously inaccessible biology, this time towards enabling binders for novel E3 ligases, with the potential to be applied to the discovery and development of new and better therapeutic options for patients."
Started in 2020, the objective of the global partnership is to discover, develop, and commercialize a pipeline of innovative small molecule therapeutics against certain high-interest, difficult-to-drug protein targets.
"We are excited that our team’s work, with support from AbbVie, has resulted in accessing two previously undruggable E3 Ligases for targeted protein degradation, and each program has the potential to drive new therapeutic opportunities for patients," said Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO. "Our delivery of three programs into lead generation further validates The Frontier Platform’s ability to systematically discover and deliver small molecules to drug undruggable targets. We look forward to progressing these novel breakthrough discoveries to help advance transformative care for patients."
About Frontier and AbbVie Partnership
Under the partnership, the companies will collaborate on the research and pre-clinical development of programs directed to novel E3 ligases, and certain immunology and oncology targets. AbbVie will reimburse Frontier’s R&D costs through defined stages of pre-clinical development. Upon successful completion, AbbVie will assume full responsibility for global development and commercialization activities and costs for the programs. Frontier will retain an option to share development activities and expenses for certain oncology programs through the completion of Phase 2. Frontier will be eligible to receive success-based development and commercial milestone payments that could potentially exceed $1 billion, in addition to royalty payments on commercialized products. AbbVie retains the right to expand the collaboration in the future by exercising options to a defined number of additional targets. The collaboration excludes all of Frontier’s internal programs for which Frontier retains exclusive global rights.